Wire · opportunities
Roche's Lunsumio combo meets primary endpoint in Phase III follicular lymphoma trial
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 17 September 2026 · Fusion42 review
Roche’s mosunetuzumab-lenalidomide combo achieved a statistically significant improvement in progression-free survival over rituximab plus lenalidomide in a Phase III trial for relapsed or refractory follicular lymphoma, setting the stage for full FDA approval and potential label expansion.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You now have clear regulatory momentum for bispecific antibody combos in lymphoma as Roche moves from accelerated to full approval, shifting competition towards demonstrated survival benefit rather than just early response rates.
◆ Coverage
1 source · 17 Sep 2026
◆ Related on Wire
◆ Topics